Advances in the treatment of inflammatory bowel disease (IBD) in the past decade include 5-aminosalicylic preparations with fewer adverse effects; new, rapidly metabolized corticosteroids; and new agents targeted at refractory or complicated IBD. Dr Tung and Dr Warner discuss the use of these and more traditional drugs in patients with colonic Crohn's disease and ulcerative colitis, stressing the need for individualized treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3810/pgm.2002.11.1344 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!